

Medical Necessity Guidelines Corneal Collagen Cross-Linking

Policy Number: 015

Contents

Overview.....	1
Medicare Advantage	1
Mass General Brigham ACO	1
One Care and Senior Care Options (SCO).....	2
Commercial and Qualified Health Plans.....	2
Definitions	3
Codes	3
Summary of Evidence	3
Effective Dates.....	4
References	4

Overview

The purpose of this document is to describe the guidelines Mass General Brigham Health Plan utilizes to determine medical appropriateness for corneal collagen cross-linking. The treating specialist must request prior authorization for the procedure.

Medicare Advantage

Prior Authorization Required	Yes ☒ No ☐
------------------------------	---

Mass General Brigham Health Plan uses guidance from the Centers for Medicare and Medicaid Services (CMS) for medical necessity determinations for its Medicare Advantage plan members. National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), Local Coverage Articles (LCAs), and documentation included in the Medicare manuals are the basis for medical necessity determinations. When there is no guidance from CMS for the requested service, Mass General Brigham Health Plan's medical policies are used for medical necessity determinations. **As of Mass General Brigham Health Plan's most recent policy review, CMS offered no guidance for corneal collagen cross-linking. Refer to the Commercial and Qualified Health Plan section for medical necessity information.**

Mass General Brigham ACO

Prior Authorization Required (use code 66999 in place of 0402T)	Yes ☒ No ☐
Not covered	0402T

Mass General Brigham Health Plan uses guidance from MassHealth for medical necessity determinations for its Mass General Brigham ACO members. When there is no guidance from MassHealth for the requested service, Mass General Brigham Health Plan's medical policies are used for medical necessity determinations. **As of Mass General Brigham Health Plan's most recent policy review, MassHealth offered no guidance for corneal**

collagen cross-linking. Refer to Commercial and Qualified Health Plan section for medical necessity information.

One Care and Senior Care Options (SCO)

Prior Authorization Required	Yes ☒ No ☐
------------------------------	---

Mass General Brigham Health Plan uses guidance from CMS for medical necessity determinations for its One Care and SCO plan members. NCDs, LCDs, LCAs, and documentation included in the Medicare manuals are the basis for medical necessity determinations. When there is no guidance from CMS for the requested service, or the member does not meet all of the medical necessity criteria for the requested service, Mass General Brigham Health Plan uses medical necessity guidelines from MassHealth. **See Medicare Advantage criteria and exclusions above. If Medicare Advantage criteria are not met, then MassHealth criteria are applied.**

Commercial and Qualified Health Plans

Prior Authorization Required	Yes ☒ No ☐
------------------------------	---

Mass General Brigham Health Plan covers corneal collagen cross-linking for the treatment of progressive corneal thinning caused by progressive keratoconus or corneal ectasia following refractive surgery. Mass General Brigham Health Plan favors the epithelium-off protocol; however, Mass General Brigham will approve the epithelium-on protocol when the epithelium-off protocol is contraindicated or unavailable.

Mass General Brigham Health Plan covers medically necessary corneal collagen cross-linking treatment in the following instances:

1. For members with **progressive keratoconus** corneal collagen cross-linking is considered medically necessary when all of the following conditions are met:
 - a. Diagnosis of keratoconus based on keratometry and corneal mapping; and
 - b. Any of the following changes have occurred within 24 months:
 - i. increase of 1.00 diopters (D) or more in the steepest keratometry measurement; or
 - ii. increase of 1.00 D or more in manifest cylinder; or
 - iii. increase of 0.50 D or more in manifest refraction spherical equivalent (MRSE); and
 - c. Member is age 14 years or older; and
 - d. Corrected distance visual acuity (CDVA) worse than 20/20 with properly fitted spectacles or contact lenses; and
 - e. Corneal thickness 300 microns or more; and
 - f. No history of corneal or systemic disease that would interfere with healing post-procedure.
2. For members with a diagnosis of **corneal ectasia following refractive surgery**, corneal collagen cross-linking is considered medically necessary when all of the following conditions are met:
 - a. Member is age 14 years of age or older; and
 - b. Consistent axial topography pattern, including relative inferior steepening with inferior-superior difference of at least 1.5 diopters; and
 - c. Corrected distance visual acuity worse than 20/20; and



- d. Corneal thickness of at least 300 micrometers at the thinnest area; and
- e. No history of corneal or systemic disease that would interfere with healing post-procedure.

Exclusions

Mass General Brigham Health Plan does not provide coverage for retreatment of an eye previously treated with corneal collagen cross-linking or coverage of corneal collagen cross-linking for conditions that do not meet the criteria noted above.

Definitions

Corneal Collagen Cross-linking: A procedure used that uses riboflavin drops, ultraviolet light, and a photosensitizer to strengthen bonds in the cornea. Ultraviolet (UV) light is combined with riboflavin eye drops to create new collagen crosslinks in the cornea, strengthening and stabilizing the cornea. The viscous riboflavin solution is applied to the eye topically before and during UV irradiation using the KXL System.

Ectasia: A serious long-term complication of laser in situ keratomileusis (LASIK) surgery and photorefractive keratectomy. It is similar to keratoconus but occurs postoperatively and primarily affects older populations.

Keratoconus: A bilateral dystrophy characterized by progressive ectasia (paracentral steepening and stromal thinning) that impairs visual acuity. While frequently diagnosed at a young age, the progression of keratoconus is variable.

Codes

The following codes are included below for informational purposes only; inclusion of a code does not constitute or imply coverage or reimbursement.

Authorized Code	Code Description
0402T	Collagen cross-linking of cornea (including removal of the corneal epithelium and intraoperative pachymetry when performed)
J2787	Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL
J2789	Riboflavin 5'-phosphate, ophthalmic solution (epioxahd/epioxa), up to 2 ml
66999 (Mass General Brigham ACO only)	Other procedures of the anterior segment of the eye

Summary of Evidence

Corneal collagen cross-linking (CXL) has been extensively studied for its efficacy and safety in treating keratoconus and corneal ectasia. For treatment of progressive keratoconus, Alnawaiseh et al. (2015) observed that corneal densitometry peaks within 1–3 months post-CXL and returns to preoperative levels by one year, achieving clarity comparable to healthy corneas by two years. Poli et al. (2015) demonstrated six-year effectiveness of epithelium-off CXL in individuals with both progressive keratoconus and corneal ectasia following refractive surgery, stabilizing ectasia in 89% of cases, improving visual acuity, and maintaining keratometry stability. Hersh et al. (2011, 2017) conducted a multicenter RCT of CXL for treatment of corneal ectasia following refractive surgery and concluded that CXL improved visual acuity and maximum keratometry compared with sham control. Enders et al. (2023) confirmed that improvements of visual outcomes can persist for 13 years following CXL treatment of keratoconus.

A substantial body of evidence has compared epithelium-on and epithelium-off techniques. Borchert et al. (2024), in a meta-analysis of 27 studies and over 1,600 eyes, found no significant difference between epithelium-off and epithelium-on CXL in corrected visual acuity or maximum keratometry at 12 months, though epithelium-off produced somewhat better uncorrected visual acuity and greater corneal thinning. symplr's 2026



evidence brief similarly evaluated epithelium-on protocols and reinforced their viability as an alternative to standard epithelium-off treatment. Beckman et al. (2026), in a phase 3 sham-controlled RCT of oxygen-enriched epithelium-on CXL (Epiox), found the treatment efficacious in reducing corneal curvature and safe and well tolerated in both adult and pediatric keratoconus patients, a finding supported by the manufacturer's package insert (Epiox, 2025) and further characterized from a commercial standpoint by IPD Analytics (2025).

Multiple studies have compared accelerated and conventional CXL protocols (Eissa and Yassin, 2019; Madeira et al., 2019; Marafon et al., 2020; Shajari et al., 2019), finding both approaches to be safe and effective, with accelerated CXL offering the benefit of shorter treatment times.

Pediatric-specific protocols were reviewed by Fard et al. (2020), Tian et al. (2017), and Turhan et al. (2020), each concluding that CXL, whether accelerated or conventional, effectively halts keratoconus progression in children and adolescents with an acceptable safety profile, a population of particular concern given the more rapid disease course typically seen at younger ages.

Craig et al. (2014) highlighted the effectiveness of epithelium-off CXL using riboflavin and UV-A in their systematic review that included patients with both progressive keratoconus and post-Lasik ectasia. Meta-analyses by Kobashi and Rong (2017) and Meiri et al. (2016) have confirmed the ability of CXL to halt keratoconus progression and improve visual function. Meta-analysis by Wan et al. (2017) concluded that CXL effectively stabilized ectasia and improved visual function in patients following refractive surgery.

A Cochrane review by Sykakis et al (2015) highlighted the generally low quality of evidence, including the high risk of bias in available RCTs. Reviews by NICE (2013), Hayes Inc. (2018), and the AAO Cornea/External Disease Practice Pattern Panel (Jhanji et al., 2023) offered guidance on clinical practice, underscoring CXL's broad applicability, while UpToDate (Wayman, 2024) provides consolidated point-of-care guidance on diagnosis and management of keratoconus more generally. While CXL is generally safe and effective, potential complications such as haze formation and the possibility of recurrence in some cases should be considered.

Criteria in this policy are based primarily on inclusion criteria from the major trials demonstrating safety and efficacy, including Hersh (2017) and Beckman et al. (2026). Mass General Brigham Health Plan finds that evidence of safety and efficacy are lacking for patients who do not meet these criteria.

Effective Dates

November 1, 2026: Ad hoc review. Reformatted policy. Extended coverage to the epithelium-on protocol. Updated code list, summary of evidence, and references. Added exclusion for retreatment.

January 2026: Annual update. Updated prior authorization table and added variation for One Care and SCO members. Fixed code disclaimer and typos.

March 2025: Ad hoc update. Summary of evidence added. References updated.

November 2024: Annual update. Code table updated. Clarified Medicare Variation language. Added MassHealth Variation.

November 2023: Annual update. Medicare Advantage added to table.

December 2022: Annual update. Criteria changed under both #1 and #2 to include list of conditions.

November 2021: Annual update. References updated.

November 2020: Annual update. References updated.

November 2019: Annual update. References updated.

January 2019: Ad hoc update. Code update.

October 2018: Effective date.

References



Alnawaiseh M, Rosentreter A, Eveslage M, Eter N, Zuhagen L. Changes in Corneal Transparency After Cross-linking for Progressive Keratoconus: Long-term Follow-up. *Journal of Refractive Surgery* 2015;31(9):614–8.

Beckman KA, Parkhurst GD, Lee JH, et al. Randomized, Controlled Study to Evaluate the Safety and Efficacy of Oxygen-Enriched Epithelium-On Corneal Cross-Linking for the Treatment of Keratoconus. *Ophthalmol Ther*. 2026 Apr;15(4):1463-1484. doi: 10.1007/s40123-026-01364-7. Epub 2026 Mar 13. PMID: 41824263; PMCID: PMC13046903.

Borchert GA, Kandel H, Watson SL. Epithelium-on versus epithelium-off corneal collagen crosslinking for keratoconus: a systematic review and meta-analysis. *Graefes Arch Clin Exp Ophthalmol*. 2024 Jun;262(6):1683-1692. doi: 10.1007/s00417-023-06287-8. Epub 2023 Nov 8. PMID: 37938377; PMCID: PMC11106102.

Craig JA, Mahon J, Yellowlees A, et al. Epithelium-off photochemical corneal collagen cross-linkage using riboflavin and ultraviolet a for keratoconus and keratectasia: a systematic review and meta-analysis. *Ocul Surf*. 2014 Jul;12(3):202-14. doi: 10.1016/j.jtos.2014.05.002. Epub 2014 May 14. PMID: 24999102.

Eissa SA, Yassin A. Prospective, randomized contralateral eye study of accelerated and conventional corneal cross-linking in pediatric keratoconus. *Int Ophthalmol*. 2019 May;39(5):971-979. doi: 10.1007/s10792-018-0898-y. Epub 2018 Mar 21. PMID: 29564806.

Enders C, Vogel D, Dreyhaupt J, et al. Corneal cross-linking in patients with keratoconus: up to 13 years of follow up. *Graefes Arch Clin Exp Ophthalmol*. 2023;261(4):1037.

Epioxa [package insert]. Burlington, MA: Avedro, Glaukos. October 2025.

Fard AM, Reynolds AL, Lillvis JH, Nader ND. Corneal collagen cross-linking in pediatric keratoconus with three protocols: a systematic review and meta-analysis. *J AAPOS*. 2020 Dec;24(6):331-336. doi: 10.1016/j.jaapos.2020.08.013. Epub 2020 Dec 3. PMID: 33279597.

HAYES Directory Report™. Comparative effectiveness review. Corneal Crosslinking for treatment of keratoconus. PA: HAYES, Inc., ©2018 Winifred S. Hayes, Inc. Feb 2018.

Hersh PS, Greenstein SA, Fry KL. Corneal collagen crosslinking for keratoconus and corneal ectasia: One-year results. *J Cataract Refract Surg*. Jan 2011;37(1):149-160. PMID 21183110.

Hersh PS, Stulting RD, Muller D, et al. U.S. multicenter clinical trial of corneal collagen crosslinking for treatment of corneal ectasia after refractive surgery. *Ophthalmology*. Oct 2017;124(10):1475-1484. PMID 28655538

IPD Analytics. Rx brief; ophthalmology: Epioxa/Epioxa HD (riboflavin 5'-phosphate ophthalmic solution) for Keratoconus. Nov 2025. Accessed on 7/14/2026 from https://secure.ipdanalytics.com/User/Handler/ViewReport.ashx?type=RP&file=s3%3a%2f%2fipdanalytics%2fReports%2fIPD+Analytics_RxBrief_Epioxa+and+Epioxa+HD+for+Keratoconus_11+2025_1.pdf.

Jhanji V, Ahmad S, Amescua G, et al; Cornea/External Disease Preferred Practice Pattern Panel. Corneal ectasia preferred practice pattern®. Sep 2023. Accessed on 7/14/2026 from <https://www.aaojournal.org/action/showPdf?pii=S0161-6420%2824%2900010-1>.

Kobashi H, Rong SS. Corneal Collagen Cross-Linking for Keratoconus: Systematic Review. *BioMed Research International*. 2017;2017:8145651. doi:10.1155/2017/8145651.

Madeira C, Vasques A, Beato J, et al. Transepithelial accelerated versus conventional corneal collagen crosslinking in patients with keratoconus: a comparative study. *Clinical Ophthalmology* 2019;Volume 13:445–52



Marafon SB, Kwitko S, Marinho DR. Long-term results of accelerated and conventional corneal cross-linking. *Int Ophthalmol*. 2020 Oct;40(10):2751-2761. doi: 10.1007/s10792-020-01462-w. Epub 2020 Jun 13. PMID: 32535751.

Meiri Z, Keren S, Rosenblatt A, et al. Efficacy of corneal collagen cross-linking for the treatment of keratoconus: a systematic review and meta-analysis. *Cornea*. Mar 2016;35(3):417-428. PMID 26751990

National Institute for Health and Care Excellence (NICE). Photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus and keratectasia [IPG466]. 2013; <https://www.nice.org.uk/guidance/ipg466>. Accessed October 1, 2019

Poli M, Lefevre A, Auxenfans C, Burillon C. Corneal Collagen Cross-linking for the Treatment of Progressive Corneal Ectasia: 6-Year Prospective Outcome in a French Population. *Am J Ophthalmol*. 2015;160(4):654-662.e1. doi:10.1016/j.ajo.2015.06.027.

Shajari M, Kolb CM, Agha B, et al. Comparison of standard and accelerated corneal cross-linking for the treatment of keratoconus: a metaanalysis. *Acta Ophthalmol*. 2019 Feb;97(1):e22-e35. doi: 10.1111/aos.13814. Epub 2018 May 31.

Singh T, Taneja M, Murthy S, Vaddavalli PK. Evaluation of safety and efficacy of different protocols of collagen cross linking for keratoconus. *Rom J Ophthalmol*. 2020 Apr-Jun;64(2):158-167. PMID: 32685782; PMCID: PMC7339692.

sympplr. Evidence analysis research brief: epithelium-on corneal collagen cross-linking for treatment of progressive keratoconus. Mar 13 2026. Accessed on 7/14/2026 from <https://evidence.hayesinc.com/report/earb.keratoconus6251>.

Sykakis E, Karim R, Evans JR, et al. Corneal collagen cross-linking for treating keratoconus. *Cochrane Database Syst Rev*. Mar 24 2015;3(3):CD010621. PMID 25803325

Tian M, Ma P, Zhou W, Feng J, Mu G. Outcomes of corneal crosslinking for central and paracentral keratoconus. *Medicine*. March 2017 96:10(e6247)

Turhan SA, Yargi B, Toker E. Efficacy of Conventional Versus Accelerated Corneal Cross-linking in Pediatric Keratoconus: Two-Year Outcomes. *J Refract Surg*. 2020 Apr 1;36(4):265-269. doi: 10.3928/1081597X-20200302-01. PMID: 32267958.

Vinciguerra P, Rosetta P, Legrottaglie EF, et al. Iontophoresis CXL With and Without Epithelial Debridement Versus Standard CXL: 2-Year Clinical Results of a Prospective Clinical Study. *J Refract Surg*. 2019 Mar 1;35(3):184-190.

Wan Q, Wang D, Ye H, Tang J, Han Y. A review and meta-analysis of corneal cross-linking for post-laser vision correction ectasia. *Journal of Current Ophthalmology*. 2017;29(3):145-153. doi:10.1016/j.joco.2017.02.008.

Wayman LL. Keratoconus. UpToDate. May 31, 2024. Accessed on 7/14/2026 from <https://www.uptodate.com/contents/keratoconus>.

